{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-098637","form_type":"8-K","ticker":null,"cik":"0001711933","company_name":"Akoya Biosciences, Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.953285+00:00","generated_at":"2026-06-10T23:28:56.466665+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Akoya Biosciences amends bylaws to adopt Universal Proxy Rules and DGCL updates","bullets":["Enhanced disclosure requirements for stockholder director nominations and other proposals.","Requires stockholders to represent intent to solicit proxies under Rule 14a-19 for non-company nominees.","Company will disregard nominations if stockholder fails to comply with Rule 14a-19 requirements.","Prohibits placeholder nominees; white proxy card reserved exclusively for the Board.","Updates stockholder list provisions to reflect recent Delaware General Corporation Law amendments."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-098637","json":"https://secwatch.observer/filing/0001104659-23-098637.json","markdown":"https://secwatch.observer/filing/0001104659-23-098637.md","text":"https://secwatch.observer/filing/0001104659-23-098637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711933/000110465923098637/0001104659-23-098637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711933/000110465923098637/tm2325584d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:28:56.466665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5eebd0ed5a23a3ae8eed3225e7e59ac61db6dd7","claim":"Akoya Biosciences, Inc.: Amended and restated bylaws to adopt Rule 14a-19 (Universal Proxy Rules), reflect recent changes to Delaware General Corporation Law, and make other updates (effective 2023-08-31).","evidence_excerpt":"On August 31, 2023, in connection with the adoption of Rule 14a-19 (the “Universal Proxy Rules”) under the Securities Exchange Act of 1934, as amended, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of Akoya Biosciences, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711933/000110465923098637/0001104659-23-098637-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-08-31"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}